Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Dyslipidemia

Free Subscription Articles published in Atherosclerosis Retrieve available abstracts of 154 articles: HTML format

Single Articles

August 2024
1. QI X, Zhang Y, Wang Y, Sun J, et al
   Prognostic value of serum immunoglobulin M levels in patients with acute coronary syndrome.
   Atherosclerosis. 2024;395:117552.
   PubMed     Abstract available
   
   
   
2. SCHMIDT-TRUCKSASS A, Lichtenstein AH, von Kanel R
   Lifestyle factors as determinants of atherosclerotic cardiovascular health.
   Atherosclerosis. 2024;395:117577.
   PubMed     Abstract available
   
   
   June 2024
3. MASROURI S, Tamehri Zadeh SS, Shapiro MD, Khalili D, et al
   Impact of optimal cholesterol levels on subclinical atherosclerosis in the absence of risk factors in young adults.
   Atherosclerosis. 2024;393:117520.
   PubMed     Abstract available
   
   
   May 2024
4. BERBERICH AJ, Hegele RA
   Pancreatitis risk in genetic subtypes of multifactorial chylomicronemia syndrome.
   Atherosclerosis. 2024;392:117528.
   PubMed    
   
   
   April 2024
5. HENDY LE, Spees LP, Tak C, Carpenter DM, et al
   An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients.
   Atherosclerosis. 2024;393:117541.
   PubMed     Abstract available
   
   
   
6. HARADA-SHIBA M
   How can we improve the prognosis of patients with homozygous familial hypercholesterolemia?
   Atherosclerosis. 2024 Apr 16:117551. doi: 10.1016/j.atherosclerosis.2024.117551.
   PubMed    
   
   
   
7. IBRAHIM S, Nurmohamed NS, Nierman MC, de Goeij JN, et al
   Enhanced identification of familial hypercholesterolemia using central laboratory algorithms.
   Atherosclerosis. 2024;393:117548.
   PubMed     Abstract available
   
   
   
8. BASHIR B, Kwok S, Wierzbicki AS, Jones A, et al
   Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: Implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS).
   Atherosclerosis. 2024;391:117476.
   PubMed     Abstract available
   
   
   March 2024
9. REIJMAN MD, Kusters DM, Groothoff JW, Arbeiter K, et al
   Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN.
   Atherosclerosis. 2024;392:117525.
   PubMed     Abstract available
   
   
   
10. ALONSO R, Arroyo-Olivares R, Diaz-Diaz JL, Fuentes-Jimenez F, et al
    Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.
    Atherosclerosis. 2024 Mar 16:117516. doi: 10.1016/j.atherosclerosis.2024.117516.
    PubMed     Abstract available
    
    
    
11. MELNES T, Bogsrud MP, Christensen JJ, Rundblad A, et al
    Gene expression profiling in elderly patients with familial hypercholesterolemia with and without coronary heart disease.
    Atherosclerosis. 2024;392:117507.
    PubMed     Abstract available
    
    
    
12. ESCATE R, Padro T, Perez de Isla L, Fuentes F, et al
    Circulating miR-6821-5p levels and coronary calcification in asymptomatic familial hypercholesterolemia patients.
    Atherosclerosis. 2024;392:117502.
    PubMed     Abstract available
    
    
    
13. SCHLEGEL A
    Diagnostic challenge of an APOB variant of uncertain significance resolved by transheterozygosity with a pathological LDLR variant and clinical response to therapy.
    Atherosclerosis. 2024;390:117460.
    PubMed    
    
    
    February 2024
14. GUAY SP, Paquette M, Taschereau A, Girard L, et al
    Acute pancreatitis risk in multifactorial chylomicronemia syndrome depends on the molecular cause of severe hypertriglyceridemia.
    Atherosclerosis. 2024 Feb 27:117489. doi: 10.1016/j.atherosclerosis.2024.117489.
    PubMed     Abstract available
    
    
    
15. AGBAJE AO
    Increasing lipids with risk of worsening cardiac damage in 1595 adolescents: A 7-year longitudinal and mediation study.
    Atherosclerosis. 2024;389:117440.
    PubMed     Abstract available
    
    
    
16. NOVO G, Arcari L, Stiermaier T, Alaimo C, et al
    Statin therapy and outcome in Takotsubo syndrome patients: Results from the multicenter international GEIST registry.
    Atherosclerosis. 2024;389:117421.
    PubMed     Abstract available
    
    
    January 2024
17. RAGGI P, Takyar FM, Gadiyaram V, Zhang C, et al
    Differential effect of atorvastatin and pravastatin on thoracic spine attenuation: A sub-analysis of a randomized clinical trial.
    Atherosclerosis. 2024;388:117425.
    PubMed     Abstract available
    
    
    December 2023
18. WODAJE T, Mahdi A, Venkateshvaran A, Habel H, et al
    Higher prevalence of coronary microvascular dysfunction in asymptomatic individuals with high levels of lipoprotein(a) with and without heterozygous familial hypercholesterolaemia.
    Atherosclerosis. 2023;389:117439.
    PubMed     Abstract available
    
    
    
19. ANDRADE MM, Neto Goncalves T, Cruz D
    Familial hypercholesterolemia diagnostic challenge: Is Artificial Intelligence the key?
    Atherosclerosis. 2023 Dec 27:117435. doi: 10.1016/j.atherosclerosis.2023.117435.
    PubMed    
    
    
    
20. FISHBEIN I, Inamdar VV, Alferiev IS, Bratinov G, et al
    Hypercholesterolemia exacerbates in-stent restenosis in rabbits: Studies of the mitigating effect of stent surface modification with a CD47-derived peptide.
    Atherosclerosis. 2023;390:117432.
    PubMed     Abstract available
    
    
    November 2023
21. MOLOKHIA M, Wierzbicki AS, Williams H, Kirubakaran A, et al
    Assessment of ethnic inequalities in diagnostic coding of familial hypercholesterolaemia (FH): A cross-sectional database study in Lambeth, South London.
    Atherosclerosis. 2023;388:117353.
    PubMed     Abstract available
    
    
    
22. ZUBIRAN R, Vargas-Vazquez A, Olvera FDR, Cruz-Bautista I, et al
    Performance of the enhanced Sampson-NIH equation for VLDL-C and LDL-C in a population with familial combined hyperlipidemia.
    Atherosclerosis. 2023;386:117364.
    PubMed     Abstract available
    
    
    
23. HOLVEN KB, Roeters van Lennep J
    Sex differences in lipids: A life course approach.
    Atherosclerosis. 2023;384:117270.
    PubMed     Abstract available
    
    
    
24. GOLDBERG AC, Banach M, Catapano AL, Duell PB, et al
    Evaluation of the efficacy and safety of bempedoic acid in women and men: Pooled analyses from phase 3 trials.
    Atherosclerosis. 2023;384:117192.
    PubMed     Abstract available
    
    
    
25. GAVINA C, Araujo F, Teixeira C, Ruivo JA, et al
    Sex differences in LDL-C control in a primary care population: The PORTRAIT-DYS study.
    Atherosclerosis. 2023;384:117148.
    PubMed     Abstract available
    
    
    October 2023
26. KATZMANN JL, Laufs U
    Liver transplantation for homozygous familial hypercholesterolemia: Cure for a genetic disease?
    Atherosclerosis. 2023 Oct 16:117337. doi: 10.1016/j.atherosclerosis.2023.117337.
    PubMed    
    
    
    
27. JUNNA N, Ruotsalainen S, Ripatti P, FinnGen, et al
    Novel Finnish-enriched variants causing severe hypercholesterolemia and their clinical impact on coronary artery disease.
    Atherosclerosis. 2023 Oct 12:117327. doi: 10.1016/j.atherosclerosis.2023.117327.
    PubMed     Abstract available
    
    
    
28. PAGE MM, Hardikar W, Alex G, Bates S, et al
    Long-term outcomes of liver transplantation for homozygous familial hypercholesterolaemia in Australia and New Zealand.
    Atherosclerosis. 2023 Oct 10:117305. doi: 10.1016/j.atherosclerosis.2023.117305.
    PubMed     Abstract available
    
    
    
29. CHAIT A, Eckel RH, Vrablik M, Zambon A, et al
    Lipid-lowering in diabetes: An update.
    Atherosclerosis. 2023 Oct 6:117313. doi: 10.1016/j.atherosclerosis.2023.117313.
    PubMed     Abstract available
    
    
    
30. RAJA V, Aguiar C, Alsayed N, Chibber YS, et al
    Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook.
    Atherosclerosis. 2023;383:117312.
    PubMed     Abstract available
    
    
    
31. SANTOS RD
    Improving pediatric familial hypercholesterolemia diagnosis by looking deeper into families.
    Atherosclerosis. 2023 Oct 1:117317. doi: 10.1016/j.atherosclerosis.2023.117317.
    PubMed    
    
    
    September 2023
32. ALBUQUERQUE J, Medeiros AM, Alves AC, Jannes CE, et al
    Generation and validation of a classification model to diagnose familial hypercholesterolaemia in adults.
    Atherosclerosis. 2023;383:117314.
    PubMed     Abstract available
    
    
    August 2023
33. CASULA M, Gazzotti M, Capra ME, Olmastroni E, et al
    Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study.
    Atherosclerosis. 2023 Aug 12:117231. doi: 10.1016/j.atherosclerosis.2023.117231.
    PubMed     Abstract available
    
    
    
34. MARTAGON AJ, Zubiran R, Gonzalez-Arellanes R, Praget-Bracamontes S, et al
    HDL abnormalities in type 2 diabetes: Clinical implications.
    Atherosclerosis. 2023 Aug 3:117213. doi: 10.1016/j.atherosclerosis.2023.117213.
    PubMed     Abstract available
    
    
    
35. SHAPIRO MD, Taub PR, Louie MJ, Lei L, et al
    Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials.
    Atherosclerosis. 2023;378:117182.
    PubMed     Abstract available
    
    
    
36. MURPHY JM, Jeong K, Tran DTK, Cioffi DL, et al
    Nuclear FAK in endothelium: An intrinsic inhibitor of NF-kappaB activation in atherosclerosis.
    Atherosclerosis. 2023;379:117189.
    PubMed     Abstract available
    
    
    July 2023
37. SIMONEN P, Oorni K, Sinisalo J, Strandberg TE, et al
    High cholesterol absorption: A risk factor of atherosclerotic cardiovascular diseases?
    Atherosclerosis. 2023;376:53-62.
    PubMed     Abstract available
    
    
    June 2023
38. JONES A, Peers K, Wierzbicki AS, Ramachandran R, et al
    Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS).
    Atherosclerosis. 2023;375:67-74.
    PubMed     Abstract available
    
    
    
39. CASAS-DEZA D, Espina S, Martinez-Sapina A, Del Moral-Bergos R, et al
    Triglyceride-rich lipoproteins and insulin resistance in patients with chronic hepatitis C receiving direct-acting antivirals.
    Atherosclerosis. 2023;375:59-66.
    PubMed     Abstract available
    
    
    
40. COSIN-SALES J, Campuzano Ruiz R, Diaz Diaz JL, Escobar Cervantes C, et al
    Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain.
    Atherosclerosis. 2023;375:38-44.
    PubMed     Abstract available
    
    
    May 2023
41. DOI T, Langsted A, Nordestgaard BG
    Dual elevated remnant cholesterol and C-reactive protein in myocardial infarction, atherosclerotic cardiovascular disease, and mortality.
    Atherosclerosis. 2023 May 13:S0021-9150(23)00204.
    PubMed     Abstract available
    
    
    
42. DOU Y, Chen B, Yu X, Ma D, et al
    Effectiveness of Internet-based health management in patients with dyslipidemia: A four-year longitudinal study.
    Atherosclerosis. 2023;376:34-42.
    PubMed     Abstract available
    
    
    
43. SONMEZ A, Demirci I, Haymana C, Tasci I, et al
    Clinical characteristics of adult and paediatric patients with familial hypercholesterolemia: A real-life cross-sectional study from the Turkish National Database.
    Atherosclerosis. 2023;375:9-20.
    PubMed     Abstract available
    
    
    
44. VAN EENIGE R, Ying Z, Tramper N, Wiebing V, et al
    Combined glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonism attenuates atherosclerosis severity in APOE*3-Leiden.CETP mice.
    Atherosclerosis. 2023;372:19-31.
    PubMed     Abstract available
    
    
    
45. RISIKESAN J, Heeboll S, Kumarathas I, Funck KL, et al
    Exercise increases myocardial free fatty acid oxidation in subjects with metabolic dysfunction-associated fatty liver disease.
    Atherosclerosis. 2023;372:10-18.
    PubMed     Abstract available
    
    
    April 2023
46. RODRIGUEZ-BORJABAD C, Narveud I, Christensen JJ, Ibarretxe D, et al
    Association between Nordic and Mediterranean diets with lipoprotein phenotype assessed by (1)HNMR in children with familial hypercholesterolemia.
    Atherosclerosis. 2023;373:38-45.
    PubMed     Abstract available
    
    
    
47. SCHREUDER MM, Hamkour S, Siegers KE, Holven KB, et al
    LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis.
    Atherosclerosis. 2023 Apr 13:S0021-9150(23)00139.
    PubMed     Abstract available
    
    
    
48. HEDEGAARD BS, Bork CS, Kanstrup HL, Thomsen KK, et al
    Genetic testing increases the likelihood of a diagnosis of familial hypercholesterolaemia among people referred to lipid clinics: Danish national study.
    Atherosclerosis. 2023;373:10-16.
    PubMed     Abstract available
    
    
    March 2023
49. TADA H, Nomura A, Nohara A, Usui S, et al
    Attainment of the low-density lipoprotein cholesterol treatment target and prognosis of heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2023 Mar 17:S0021-9150(23)00103.
    PubMed     Abstract available
    
    
    
50. STANKOV S, Cuchel M
    Gene editing for dyslipidemias: New tools to "cut" lipids.
    Atherosclerosis. 2023;368:14-24.
    PubMed     Abstract available
    
    
    February 2023
51. LI N, Zhang X, Zhang M, Wu L, et al
    Associations of genetically determined lipid traits and lipid-modifying agents with the risk of diabetic retinopathy: A Mendelian randomization study.
    Atherosclerosis. 2023;369:9-16.
    PubMed     Abstract available
    
    
    January 2023
52. TSABAN G, Peles I, Barrett O, Abramowitz Y, et al
    Nonobstructive coronary atherosclerosis is associated with adverse prognosis among patients diagnosed with myocardial infarction without obstructive coronary arteries.
    Atherosclerosis. 2023;366:8-13.
    PubMed     Abstract available
    
    
    
53. AGBAJE AO, Lloyd-Jones DM, Magnussen CG, Tuomainen TP, et al
    Cumulative dyslipidemia with arterial stiffness and carotid IMT progression in asymptomatic adolescents: A simulated intervention longitudinal study using temporal inverse allocation model.
    Atherosclerosis. 2023;364:39-48.
    PubMed     Abstract available
    
    
    December 2022
54. FARIA R, Saramago P, Cox E, Weng S, et al
    How does cholesterol burden change the case for investing in familial hypercholesterolaemia? A cost-effectiveness analysis.
    Atherosclerosis. 2022 Dec 29:S0021-9150(22)01557.
    PubMed     Abstract available
    
    
    
55. KAMSTRUP PR
    Lipoprotein(a) and familial hypercholesterolemia: Partners in crime in heritable hyperlipidemia.
    Atherosclerosis. 2022 Dec 24:S0021-9150(22)01570.
    PubMed    
    
    
    
56. COUTINHO ER, Miname MH, Rocha VZ, Bittencourt MS, et al
    Cardiovascular disease onset in old people with severe hypercholesterolemia.
    Atherosclerosis. 2022;365:9-14.
    PubMed     Abstract available
    
    
    
57. PINZON GRIMALDOS A, Pacella I, Bini S, Tucci G, et al
    ANGPTL3 deficiency associates with the expansion of regulatory T cells with reduced lipid content.
    Atherosclerosis. 2022;362:38-46.
    PubMed     Abstract available
    
    
    November 2022
58. TROMP TR, Ibrahim S, Nurmohamed NS, Peter J, et al
    Use of Lipoprotein(a) to improve diagnosis and management in clinical familial hypercholesterolemia.
    Atherosclerosis. 2022 Nov 29:S0021-9150(22)01530.
    PubMed     Abstract available
    
    
    
59. NICHOLLS SJ
    Scratching the surface of atherosclerosis: Distinguishing phenotypes of plaque erosion.
    Atherosclerosis. 2022;360:42-43.
    PubMed    
    
    
    October 2022
60. CEFALU AB, D'Erasmo L, Iannuzzo G, Noto D, et al
    Efficacy and safety of lomitapide in familial chylomicronaemia syndrome.
    Atherosclerosis. 2022;359:13-19.
    PubMed     Abstract available
    
    
    August 2022
61. MICHIKURA M, Hori M, Ogura M, Hosoda K, et al
    The impact of gene variants on the thickness and softness of the Achilles tendon in familial hypercholesterolemia.
    Atherosclerosis. 2022;358:41-46.
    PubMed     Abstract available
    
    
    
62. SVENDSEN K, Olsen T, Vinknes KJ, Mundal LJ, et al
    Risk of stroke in genetically verified familial hypercholesterolemia: A prospective matched cohort study.
    Atherosclerosis. 2022;358:34-40.
    PubMed     Abstract available
    
    
    
63. MIZUTA MH, Santos RD
    Difficulties in gauging atherosclerotic cardiovascular disease risk heterogeneity in familial hypercholesterolemia.
    Atherosclerosis. 2022 Aug 22. pii: S0021-9150(22)01389.
    PubMed    
    
    
    July 2022
64. MCKAY AJ, Gunn LH, Ray KK
    Assessing the external validity of the SAFEHEART risk prediction model in patients with familial hypercholesterolaemia in an English routine care cohort.
    Atherosclerosis. 2022 Jul 21. pii: S0021-9150(22)01352.
    PubMed     Abstract available
    
    
    June 2022
65. JAHN B, Santamaria J, Dieplinger H, Binder CJ, et al
    Familial hypercholesterolemia: A systematic review of modeling studies on screening interventions.
    Atherosclerosis. 2022;355:15-29.
    PubMed     Abstract available
    
    
    
66. TAMURA K, Kumagai T, Kobayashi K
    Possible clinical usefulness of polygenic risk scores among patients with established atherosclerotic cardiovascular disease.
    Atherosclerosis. 2022;350:100-101.
    PubMed    
    
    
    
67. LIN H, Xuan L, Xiang J, Hou Y, et al
    Changes in adiposity modulate the APOA5 genetic effect on blood lipids: A longitudinal cohort study.
    Atherosclerosis. 2022;350:1-8.
    PubMed     Abstract available
    
    
    May 2022
68. CHEMELLO K, Chan DC, Lambert G, Watts GF, et al
    Recent advances in demystifying the metabolism of lipoprotein(a).
    Atherosclerosis. 2022;349:82-91.
    PubMed     Abstract available
    
    
    
69. PEDERIVA C, Capra ME, Biasucci G, Banderali G, et al
    Lipoprotein(a) and family history for cardiovascular disease in paediatric patients: A new frontier in cardiovascular risk stratification. Data from the LIPIGEN paediatric group.
    Atherosclerosis. 2022;349:233-239.
    PubMed     Abstract available
    
    
    
70. RIDER DA, Eisermann M, Loffler K, Aleku M, et al
    Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease.
    Atherosclerosis. 2022;349:240-247.
    PubMed     Abstract available
    
    
    April 2022
71. TENG H, Gao Y, Wu C, Zhang H, et al
    Prevalence and patient characteristics of familial hypercholesterolemia in a Chinese population aged 35-75 years: Results from China PEACE Million Persons Project.
    Atherosclerosis. 2022;350:58-64.
    PubMed     Abstract available
    
    
    March 2022
72. NOTO D, Spina R, Giammanco A, Barbagallo CM, et al
    Diagnosis of familial hypercholesterolemia in a large cohort of Italian genotyped hypercholesterolemic patients.
    Atherosclerosis. 2022;347:63-67.
    PubMed     Abstract available
    
    
    
73. MULDER JWCM, Kranenburg LW, Treling WJ, Hovingh GK, et al
    Quality of life and coping in Dutch homozygous familial hypercholesterolemia patients: A qualitative study.
    Atherosclerosis. 2022 Mar 12. pii: S0021-9150(22)00136.
    PubMed     Abstract available
    
    
    February 2022
74. STOCK JK
    Homozygous Familial Hypercholesterolaemia International Clinical Collaboration (HICC) registry: Levelling up access to treatment urgently needed.
    Atherosclerosis. 2022 Feb 20. pii: S0021-9150(22)00077.
    PubMed    
    
    
    January 2022
75. PECHLANER R, Friedrich N, Staudt A, Gande N, et al
    Association of adolescent lipoprotein subclass profile with carotid intima-media thickness and comparison to adults: Prospective population-based cohort studies.
    Atherosclerosis. 2022;341:34-42.
    PubMed     Abstract available
    
    
    
76. PAQUETTE M, Baass A
    Polygenic risk scores for cardiovascular disease prediction in the clinical practice: Are we there?
    Atherosclerosis. 2022;340:46-47.
    PubMed    
    
    
    
77. CATAPANO AL, Ray KK, Tokgozoglu L
    Prevention guidelines and EAS/ESC guidelines for the treatment of dyslipidaemias: A look to the future.
    Atherosclerosis. 2022;340:51-52.
    PubMed    
    
    
    December 2021
78. TRINDER M, Vikulova D, Pimstone S, Mancini GBJ, et al
    Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia.
    Atherosclerosis. 2021;340:35-43.
    PubMed     Abstract available
    
    
    
79. TADA H, Okada H, Nohara A, Takamura M, et al
    Genetic mutations, regression of Achilles tendon thickness, and cardiovascular events among patients with familial hypercholesterolemia.
    Atherosclerosis. 2021;340:28-34.
    PubMed     Abstract available
    
    
    November 2021
80. CHAKRABORTY A, Pang J, Chan DC, Ellis KL, et al
    Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a).
    Atherosclerosis. 2021 Nov 12. pii: S0021-9150(21)01417.
    PubMed     Abstract available
    
    
    
81. SANCHEZ-RAMOS A, Fernandez-Labandera C, Vallejo-Vaz A, Bonacho EC, et al
    Prevalence of familial hypercholesterolemia phenotype and ten-year risk of cardiovascular events in a working population in primary prevention: The ICARIA study.
    Atherosclerosis. 2021;338:39-45.
    PubMed     Abstract available
    
    
    
82. TROMP TR, Cupido AJ, Reeskamp LF, Stroes ESG, et al
    Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia.
    Atherosclerosis. 2021 Nov 2. pii: S0021-9150(21)01413.
    PubMed     Abstract available
    
    
    October 2021
83. LEONARDI-BEE J, Boateng C, Faria R, Eliman K, et al
    Effectiveness of cascade testing strategies in relatives for familial hypercholesterolemia: A systematic review and meta-analysis.
    Atherosclerosis. 2021;338:7-14.
    PubMed     Abstract available
    
    
    
84. AHMED AI, Han Y, Al Rifai M, Alnabelsi T, et al
    Added prognostic value of plaque burden to computed tomography angiography and myocardial perfusion imaging.
    Atherosclerosis. 2021;334:9-16.
    PubMed     Abstract available
    
    
    September 2021
85. STOCK JK
    Global Familial Hypercholesterolaemia Studies Collaboration (FHSC).
    Atherosclerosis. 2021 Sep 23. pii: S0021-9150(21)01361.
    PubMed    
    
    
    
86. PAQUETTE M, Bernard S, Baass A
    Hemoglobin concentration, hematocrit and red blood cell count predict major adverse cardiovascular events in patients with familial hypercholesterolemia.
    Atherosclerosis. 2021;335:41-46.
    PubMed     Abstract available
    
    
    
87. KLEVMOEN M, Bogsrud MP, Retterstol K, Svilaas T, et al
    Loss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemia.
    Atherosclerosis. 2021;335:8-15.
    PubMed     Abstract available
    
    
    
88. KOSUGI T, Eriguchi M, Yoshida H, Tasaki H, et al
    Association between chronic kidney disease and new-onset dyslipidemia: The Japan Specific Health Checkups (J-SHC) study.
    Atherosclerosis. 2021;332:24-32.
    PubMed     Abstract available
    
    
    August 2021
89. MARCO-BENEDI V, Cenarro A, Laclaustra M, Larrea-Sebal A, et al
    Lipoprotein(a) in hereditary hypercholesterolemia: Influence of the genetic cause, defective gene and type of mutation.
    Atherosclerosis. 2021 Aug 23. pii: S0021-9150(21)01270.
    PubMed     Abstract available
    
    
    
90. DYRBUS K, Gasior M, Desperak P, Trzeciak P, et al
    Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry.
    Atherosclerosis. 2021;333:16-23.
    PubMed     Abstract available
    
    
    
91. TOMBLING BJ, Zhang Y, Huang YH, Craik DJ, et al
    The emerging landscape of peptide-based inhibitors of PCSK9.
    Atherosclerosis. 2021;330:52-60.
    PubMed     Abstract available
    
    
    July 2021
92. KATZMANN JL, Lehmann M, Tunnemann-Tarr A, An Haack I, et al
    Cutaneous manifestations in familial hypercholesterolaemia.
    Atherosclerosis. 2021 Jul 11. pii: S0021-9150(21)01236.
    PubMed     Abstract available
    
    
    
93. KHALIL YA, Rabes JP, Boileau C, Varret M, et al
    APOE gene variants in primary dyslipidemia.
    Atherosclerosis. 2021;328:11-22.
    PubMed     Abstract available
    
    
    
94. ALVES AC, Azevedo S, Benito-Vicente A, Graca R, et al
    LDLR variants functional characterization: Contribution to variant classification.
    Atherosclerosis. 2021;329:14-21.
    PubMed     Abstract available
    
    
    June 2021
95. MALO AI, Girona J, Ibarretxe D, Rodriguez-Borjabad C, et al
    Serum glycoproteins A and B assessed by (1)H-NMR in familial hypercholesterolemia.
    Atherosclerosis. 2021;330:1-7.
    PubMed     Abstract available
    
    
    
96. PAQUETTE M, Fantino M, Bernard S, Baass A, et al
    Paternal inheritance predicts earlier cardiovascular event onset in patients with familial hypercholesterolemia.
    Atherosclerosis. 2021;329:9-13.
    PubMed     Abstract available
    
    
    May 2021
97. REESKAMP LF, Nurmohamed NS, Bom MJ, Planken RN, et al
    Marked plaque regression in homozygous familial hypercholesterolemia.
    Atherosclerosis. 2021;327:13-17.
    PubMed     Abstract available
    
    
    
98. HEIDEMANN BE, Wolters FJ, Kavousi M, Gruppen EG, et al
    Adiposity and the development of dyslipidemia in APOE epsilon2 homozygous subjects: A longitudinal analysis in two population-based cohorts.
    Atherosclerosis. 2021;325:57-62.
    PubMed     Abstract available
    
    
    
99. LEE JH, Lee HS, Cho AR, Lee YJ, et al
    Relationship between muscle mass index and LDL cholesterol target levels: Analysis of two studies of the Korean population.
    Atherosclerosis. 2021;325:1-7.
    PubMed     Abstract available
    
    
    April 2021
100. BRANDTS J, Dharmayat KI, Vallejo-Vaz AJ, Azar Sharabiani MT, et al
     A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia.
     Atherosclerosis. 2021;325:46-56.
     PubMed     Abstract available
     
     
     
101. INGOE L, Potter A, Musson S, Neely D, et al
     Improving the identification of patients with a genetic diagnosis of familial hypercholesterolaemia in primary care: A strategy to achieve the NHS long term plan.
     Atherosclerosis. 2021;325:38-45.
     PubMed     Abstract available
     
     
     
102. SUADONI MT
     Benefits and harms of LDL-cholesterol-lowering therapy in older people must be established through valid and clinically relevant evidence.
     Atherosclerosis. 2021;323:57-58.
     PubMed    
     
     
     
103. ZAFEIROPOULOS S, Farmakis I, Kartas A, Arvanitaki A, et al
     Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: A pragmatic randomized controlled trial.
     Atherosclerosis. 2021;323:37-43.
     PubMed     Abstract available
     
     
     
104. LIMA JG, Helena C Nobrega L, Moura Bandeira FT, Pires Sousa AG, et al
     A novel GPIHBP1 mutation related to familial chylomicronemia syndrome: A series of cases.
     Atherosclerosis. 2021;322:31-38.
     PubMed     Abstract available
     
     
     
105. JO SH, Han SH, Kim SH, Eckel RH, et al
     Cardiovascular effects of omega-3 fatty acids: Hope or hype?
     Atherosclerosis. 2021;322:15-23.
     PubMed     Abstract available
     
     
     March 2021
106. BUONUOMO PS, Mastrogiorgio G, Leone G, Rana I, et al
     Evolocumab in the management of children <10 years of age affected by homozygous familial hypercholesterolemia.
     Atherosclerosis. 2021 Mar 28. pii: S0021-9150(21)00147.
     PubMed    
     
     
     
107. ELLINS EA, Watkins S, Rees DA, Datta DBN, et al
     Acute effect of a single session of lipoprotein apheresis on central haemodynamics in patients with familial hypercholesterolaemia.
     Atherosclerosis. 2021 Mar 27. pii: S0021-9150(21)00144.
     PubMed    
     
     
     
108. BIESECKER LG
     Correspondence on: "Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features".
     Atherosclerosis. 2021 Mar 20. pii: S0021-9150(21)00125.
     PubMed    
     
     
     
109. BANACH M, Penson PE
     Lipid-lowering therapies: Better together.
     Atherosclerosis. 2021;320:86-88.
     PubMed    
     
     
     February 2021
110. LEREN TP, Bogsrud MP
     Molecular genetic testing for autosomal dominant hypercholesterolemia in 29,449 Norwegian index patients and 14,230 relatives during the years 1993-2020.
     Atherosclerosis. 2021;322:61-66.
     PubMed     Abstract available
     
     
     
111. REESKAMP LF, Balvers M, Peter J, van de Kerkhof L, et al
     Intronic variant screening with targeted next-generation sequencing reveals first pseudoexon in LDLR in familial hypercholesterolemia.
     Atherosclerosis. 2021;321:14-20.
     PubMed     Abstract available
     
     
     January 2021
112. VUORIO A, Raal F, Kaste M, Kovanen PT, et al
     Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment.
     Atherosclerosis. 2021;320:53-60.
     PubMed     Abstract available
     
     
     
113. MARCO-BENEDI V, Laclaustra M, Bea AM, Suarez-Tembra M, et al
     Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia.
     Atherosclerosis. 2021;320:47-52.
     PubMed     Abstract available
     
     
     
114. FUTEMA M, Ramaswami U, Tichy L, Bogsrud MP, et al
     Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
     Atherosclerosis. 2021;319:108-117.
     PubMed     Abstract available
     
     
     
115. VALLEJO-VAZ AJ, Packard CJ, Ference BA, Santos RD, et al
     LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial.
     Atherosclerosis. 2021;320:1-9.
     PubMed     Abstract available
     
     
     
116. KOROSOGLOU G, Chatzizisis YS, Raggi P
     Coronary computed tomography angiography in asymptomatic patients: Still a taboo or precision medicine?
     Atherosclerosis. 2021;317:47-49.
     PubMed    
     
     
     
117. STOCK JK
     Should we treat high LDL cholesterol in 'healthy' elderly individuals?
     Atherosclerosis. 2021;317:50-51.
     PubMed    
     
     
     December 2020
118. RUBINO J, MacDougall DE, Sterling LR, Hanselman JC, et al
     Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial.
     Atherosclerosis. 2020 Dec 31. pii: S0021-9150(20)31597.
     PubMed     Abstract available
     
     
     
119. SVENDSEN K, Krogh HW, Igland J, Tell GS, et al
     2.5-fold increased risk of recurrent acute myocardial infarction with familial hypercholesterolemia.
     Atherosclerosis. 2020;319:28-34.
     PubMed     Abstract available
     
     
     
120. COUTINHO ER, Miname MH, Rocha VZ, Bittencourt MS, et al
     Familial hypercholesterolemia and cardiovascular disease in older individuals.
     Atherosclerosis. 2020;318:32-37.
     PubMed     Abstract available
     
     
     
121. SVENDSEN K, Langslet G, Krogh HW, Brinck J, et al
     Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from Scandinavia.
     Atherosclerosis. 2020;316:48-52.
     PubMed     Abstract available
     
     
     November 2020
122. PEREZ DE ISLA L, Alonso R, Gomez de Diego JJ, Muniz-Grijalvo O, et al
     Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study.
     Atherosclerosis. 2020 Nov 18. pii: S0021-9150(20)31521.
     PubMed     Abstract available
     
     
     
123. REESKAMP LF, Tromp TR, Huijgen R, Stroes ESG, et al
     Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation.
     Atherosclerosis. 2020;315:68-75.
     PubMed     Abstract available
     
     
     October 2020
124. IYEN B, Qureshi N, Weng S, Roderick P, et al
     Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: A retrospective cohort study of the UK Simon Broome register linked to national hospital records.
     Atherosclerosis. 2020 Oct 31. pii: S0021-9150(20)31491.
     PubMed     Abstract available
     
     
     September 2020
125. IQBAL Z, Ho JH, Adam S, France M, et al
     Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK.
     Atherosclerosis. 2020;313:126-136.
     PubMed     Abstract available
     
     
     
126. BERTOLINI S, Calandra S, Arca M, Averna M, et al
     Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features.
     Atherosclerosis. 2020;312:72-78.
     PubMed     Abstract available
     
     
     August 2020
127. RODRIGUEZ-NOVOA S, Rodriguez-Jimenez C, Alonso C, Rodriguez-Laguna L, et al
     Familial hypercholesterolemia: A single-nucleotide variant (SNV) in mosaic at the low density lipoprotein receptor (LDLR).
     Atherosclerosis. 2020;311:37-43.
     PubMed     Abstract available
     
     
     
128. PEPPLINKHUIZEN S, Ibrahim S, Vink R, Groot B, et al
     Electronic health records to facilitate continuous detection of familial hypercholesterolemia.
     Atherosclerosis. 2020;310:83-87.
     PubMed     Abstract available
     
     
     
129. ALJENEDIL S, Alothman L, Belanger AM, Brown L, et al
     Lomitapide for treatment of homozygous familial hypercholesterolemia: The Quebec experience.
     Atherosclerosis. 2020;310:54-63.
     PubMed     Abstract available
     
     
     July 2020
130. RALLIDIS LS, Liberopoulos EN, Vlachopoulos C, Skoumas I, et al
     Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors.
     Atherosclerosis. 2020 Jul 30. pii: S0021-9150(20)30385.
     PubMed    
     
     
     
131. FUKUMOTO K, Takemoto Y, Yoshikawa J, Norioka N, et al
     Predictors of endothelial function improvement in patients with mild hypertriglyceridemia without evidence of coronary artery disease treated with purified eicosapentaenoic acid.
     Atherosclerosis. 2020;309:27-32.
     PubMed     Abstract available
     
     
     
132. GULIZIA MM, Maggioni AP, Abrignani MG, Bilato C, et al
     Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study.
     Atherosclerosis. 2020;308:32-38.
     PubMed     Abstract available
     
     
     
133. PASTA A, Cremonini AL, Formisano E, Fresa R, et al
     Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies.
     Atherosclerosis. 2020;308:6-14.
     PubMed     Abstract available
     
     
     
134. STOCK J
     Familial hypercholesterolemia: An urgent public health priority.
     Atherosclerosis. 2020 Jul 18. pii: S0021-9150(20)30351.
     PubMed    
     
     
     
135. GALLO A, Charriere S, Vimont A, Chapman MJ, et al
     SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia.
     Atherosclerosis. 2020;306:41-49.
     PubMed     Abstract available
     
     
     May 2020
136. LAU P, Soubeyrand S, Hegele RA, Lagace TA, et al
     Molecular mechanism linking a novel PCSK9 copy number variant to severe hypercholesterolemia.
     Atherosclerosis. 2020;304:39-43.
     PubMed     Abstract available
     
     
     
137. STOCK JK
     Homozygous familial hypercholesterolaemia: New hope for getting patients to goal?
     Atherosclerosis. 2020 May 25. pii: S0021-9150(20)30230.
     PubMed    
     
     
     
138. ADEMI Z, Norman R, Pang J, Liew D, et al
     Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
     Atherosclerosis. 2020;304:1-8.
     PubMed     Abstract available
     
     
     
139. TSIMIKAS S, Stroes ESG
     The dedicated "Lp(a) clinic": A concept whose time has arrived?
     Atherosclerosis. 2020;300:1-9.
     PubMed     Abstract available
     
     
     March 2020
140. PANG J, Abraham A, Vargas-Garcia C, Bates TR, et al
     An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia.
     Atherosclerosis. 2020;298:52-57.
     PubMed     Abstract available
     
     
     
141. ADINOLFI LE, Petta S, Fracanzani AL, Coppola C, et al
     Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study.
     Atherosclerosis. 2020;296:40-47.
     PubMed     Abstract available
     
     
     
142. CHO DH, Song IS, Choi J, Gwon JG, et al
     Risk of peripheral arterial disease in patients with periodontitis: A nationwide, population-based, matched cohort study.
     Atherosclerosis. 2020;297:96-101.
     PubMed     Abstract available
     
     
     February 2020
143. LUIRINK IK, Hutten BA, Greber-Platzer S, Kolovou GD, et al
     Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry.
     Atherosclerosis. 2020;299:24-31.
     PubMed     Abstract available
     
     
     
144. NORDESTGAARD BG, Langlois MR, Langsted A, Chapman MJ, et al
     Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM.
     Atherosclerosis. 2020;294:46-61.
     PubMed     Abstract available
     
     
     January 2020
145. CHIU YW, Wu CS, Chen PC, Wei YC, et al
     Risk of acute mesenteric ischemia in patients with diabetes: A population-based cohort study in Taiwan.
     Atherosclerosis. 2020;296:18-24.
     PubMed     Abstract available
     
     
     
146. KOSKINEN JS, Kyto V, Juonala M, Viikari JSA, et al
     Childhood risk factors and carotid atherosclerotic plaque in adulthood: The Cardiovascular Risk in Young Finns Study.
     Atherosclerosis. 2020;293:18-25.
     PubMed     Abstract available
     
     
     
147. SON DH, Lee HS, Lee YJ
     Association between serum carbohydrate antigen 19-9 levels and leukoaraiosis in middle-aged and older adults: A cross-sectional study.
     Atherosclerosis. 2020;292:188-192.
     PubMed     Abstract available
     
     
     
148. MASUDA D, Miyata Y, Matsui S, Yamashita S, et al
     Omega-3 fatty acid ethyl esters improve low-density lipoprotein subclasses without increasing low-density lipoprotein-cholesterol levels: A phase 4, randomized study.
     Atherosclerosis. 2020;292:163-170.
     PubMed     Abstract available
     
     
     
149. MAEDA N, Funahashi T, Matsuzawa Y, Shimomura I, et al
     Adiponectin, a unique adipocyte-derived factor beyond hormones.
     Atherosclerosis. 2020;292:1-9.
     PubMed     Abstract available
     
     
     November 2019
150. MULDER JWCM, Galema-Boers AMH, de Jong-Verweij LM, Hazelzet JA, et al
     The development and first results of a health-related outcomes set in familial hypercholesterolemia (FH) patients: Knowledge is health.
     Atherosclerosis. 2019;293:11-17.
     PubMed     Abstract available
     
     
     
151. WALD DS, Bestwick JP
     Reaching detection targets in familial hypercholesterolaemia: Comparison of identification strategies.
     Atherosclerosis. 2019;293:57-61.
     PubMed     Abstract available
     
     
     
152. LAMIQUIZ-MONEO I, Restrepo-Cordoba MA, Mateo-Gallego R, Bea AM, et al
     Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia.
     Atherosclerosis. 2019;292:143-151.
     PubMed     Abstract available
     
     
     
153. RAMASWAMI U, Futema M, Bogsrud MP, Holven KB, et al
     Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
     Atherosclerosis. 2019;292:178-187.
     PubMed     Abstract available
     
     
     October 2019
154. RAMOS R, Masana L, Comas-Cufi M, Garcia-Gil M, et al
     Derivation and validation of SIDIAP-FHP score: A new risk model predicting cardiovascular disease in familial hypercholesterolemia phenotype.
     Atherosclerosis. 2019;292:42-51.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge.